Working Paper |
File Downloads |
Abstract Views |
Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets |
0 |
0 |
1 |
16 |
1 |
1 |
2 |
29 |
Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
19 |
Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
Assessing the population health impact of market interventions to improve access to antiretroviral treatment |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
COVID-19 and clinical trials |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
Competition Law, Intellectual Property, and the Pharmaceutical Sector |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
32 |
Competition and the Efficiency of Markets for Technology |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
3 |
Competition and the Efficiency of Markets for Technology |
0 |
0 |
0 |
94 |
0 |
0 |
1 |
135 |
Competition and the Efficiency of Markets for Technology |
0 |
0 |
0 |
70 |
0 |
0 |
1 |
129 |
Competition and the Efficiency of Markets for Technology |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
4 |
Competition law, intellectual property, and the pharmaceutical sector |
0 |
0 |
0 |
0 |
1 |
1 |
5 |
39 |
Did U.S. Bank Supervisors Get Tougher During the Credit Crunch? Did They Get Easier During the Banking Boom? Did It Matter to Bank Lending? |
0 |
0 |
0 |
189 |
0 |
0 |
2 |
819 |
Did U.S. bank supervisors get tougher during the credit crunch? Did they get easier during the banking boom? Did it matter to bank lending? |
0 |
0 |
0 |
138 |
0 |
0 |
0 |
532 |
Do Patents Work? Evidence from Pharmaceutical Innovation |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
16 |
Economic Issues in Assessing Potential and Nascent Competition |
0 |
0 |
0 |
0 |
1 |
1 |
5 |
12 |
Estimating the Benefits of Cancer Treatments |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
9 |
Estimating the Benefits of Innovation |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
44 |
Evolution of Market Exclusivity, Paragraph IV Challenges and Generic Penetration |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
36 |
Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act |
0 |
0 |
0 |
4 |
0 |
1 |
2 |
49 |
Government Free-riding in Research Funding |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
Hot tub time machine? What role for Towercast in EU merger control |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
Incentives for pharmaceutical innovation: What’s working, what’s lacking |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
7 |
Inefficiencies in technology transfer: theory and empirics |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
2 |
Inefficiencies in technology transfer: theory and empirics |
0 |
0 |
0 |
13 |
0 |
0 |
2 |
97 |
Inefficiencies in technology transfer: theory and empirics |
0 |
0 |
0 |
58 |
0 |
0 |
1 |
326 |
Inefficiencies in the sale of ideas: theory and empirics |
0 |
0 |
0 |
106 |
0 |
0 |
2 |
118 |
Inefficiencies in the sale of ideas: theory and empirics |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
Innovation pharmaceutique: comment combler le retard français ? |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
15 |
Intellectual Property Rights and Access to Innovation: Evidence from TRIPS |
0 |
1 |
5 |
61 |
2 |
4 |
16 |
198 |
Intellectual Property Rights and Access to Innovation: Evidence from TRIPS |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
Intellectual property rights and access to innovation: evidence from TRIPS |
0 |
0 |
0 |
0 |
1 |
2 |
4 |
37 |
Intersection of Intellectual Property and Competition Policy in Recent Cases |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
7 |
Investments in Pharmaceuticals Before and After TRIPS |
0 |
1 |
2 |
41 |
0 |
3 |
5 |
157 |
Investments in Pharmaceuticals Before and After TRIPS |
0 |
0 |
0 |
88 |
0 |
0 |
3 |
261 |
Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
53 |
Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs |
0 |
0 |
0 |
0 |
0 |
2 |
2 |
16 |
Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs |
0 |
0 |
0 |
45 |
0 |
2 |
2 |
59 |
Korean pharmaceutical industry policy: lessons for Korea |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
6 |
Productivity and competitiveness in the euro area: A view from France |
0 |
0 |
0 |
0 |
0 |
2 |
6 |
72 |
Productivity and competitiveness in the euro area: A view from France |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
11 |
Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research |
0 |
0 |
1 |
125 |
0 |
0 |
3 |
365 |
Strategic Interaction Among Governments in the Provision of a Global Public Good |
0 |
0 |
0 |
30 |
0 |
0 |
1 |
68 |
Strategic Responses to Parallel Trade |
0 |
0 |
0 |
131 |
0 |
0 |
1 |
392 |
Strategic interaction among governments in the provision of a global public good |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
18 |
Strategic interaction among governments in the provision of a global public good |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
10 |
Study for European Commission (DG Internal Market, Industry, Entrepreneurship and SMEs) on supplementary patent certificates |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
128 |
The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
3 |
The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
The Effects of Pharmaceutical Innovation on Cancer Mortality |
0 |
0 |
0 |
10 |
0 |
1 |
2 |
45 |
The Effects of Pharmaceutical Innovation on Cancer Mortality Rates |
0 |
0 |
2 |
98 |
0 |
2 |
7 |
201 |
The More We Die, The More We Sell? A Simple Test of the Home-Market Effect |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
59 |
The More We Die, The More We Sell? A Simple Test of the Home-Market Effect |
0 |
0 |
0 |
23 |
0 |
0 |
5 |
89 |
The More We Die, The More We Sell? A Simple Test of the Home-Market Effect* |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
5 |
The Single Market in Pharmaceuticals |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
The economics of new product launches and access to pharmaceutical products in the EU: A perspective on the EC’s proposed reform of the EU pharmaceutical legislation |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
10 |
Total Working Papers |
0 |
2 |
11 |
1,345 |
9 |
28 |
117 |
4,801 |